Cibus Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Cibus is gedaald met een gemiddeld jaarlijks percentage van -47%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19%. De inkomsten zijn daalde met een gemiddeld percentage van 21.2% per jaar.

Belangrijke informatie

-47.0%

Groei van de winst

29.8%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-21.2%
Rendement op eigen vermogen	-119.6%
Nettomarge	-9,856.8%
Volgende winstupdate	07 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

Will Calyxt (NASDAQ:CLXT) Spend Its Cash Wisely?

Aug 17

Opbrengsten en kosten

Hoe Cibus geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:CBUS Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	3	-292	26	51
31 Mar 24	2	-286	22	44
31 Dec 23	2	-268	16	36
30 Sep 23	1	-53	14	26
30 Jun 23	0	-33	11	15
31 Mar 23	0	-17	10	10
31 Dec 22	0	-17	11	12
30 Sep 22	2	-21	14	12
30 Jun 22	10	-22	14	12
31 Mar 22	22	-25	14	11
31 Dec 21	26	-29	15	11
30 Sep 21	38	-36	16	12
30 Jun 21	35	-38	17	11
31 Mar 21	26	-44	19	11
31 Dec 20	24	-45	21	11
30 Sep 20	14	-44	23	11
30 Jun 20	11	-45	25	12
31 Mar 20	10	-43	26	12
31 Dec 19	7	-40	25	12
30 Sep 19	4	-36	25	11
30 Jun 19	1	-33	23	11
31 Mar 19	0	-31	20	12
31 Dec 18	0	-28	18	10
30 Sep 18	0	-26	16	10
30 Jun 18	0	-32	19	13
31 Mar 18	0	-28	16	11
31 Dec 17	1	-26	15	12
30 Sep 17	0	-24	13	11
30 Jun 17	0	-13	8	6
31 Mar 17	0	-12	7	6
31 Dec 16	0	-12	7	6
31 Dec 15	1	-6	4	3

Kwaliteitswinsten: CBUS is momenteel verliesgevend.

Groeiende winstmarge: CBUS is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CBUS is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 47% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CBUS over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CBUS is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -2.3% ).

Rendement op eigen vermogen

Hoge ROE: CBUS heeft een negatief Return on Equity ( -119.58% ), omdat het momenteel verliesgevend is.

Cibus Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022

Calyxt, Inc., Annual General Meeting, Jun 01, 2022

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations